Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fenofibrate + pioglitazone
- Development stage
- Preclinical
- Lead developer
- Abbott
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination therapy consisting of fenofibrate, a PPARα agonist, and pioglitazone, a PPARγ agonist. Fenofibrate primarily improves lipid metabolism by increasing lipolysis, activating lipoprotein lipase, and reducing apoprotein C-III, while pioglitazone enhances insulin sensitivity to improve glycemic control. This dual PPAR agonist approach provides complementary benefits in managing type 2 diabetes with dyslipidemia.
02
Targets
PPARA (Peroxisome proliferator-activated receptor alpha)PPARG (Peroxisome proliferator-activated receptor gamma)
Beyond the preview
Go deeper on fenofibrate + pioglitazone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fenofibrate + pioglitazone.